-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I5lUtVSzOb5vMJoOQw/Yqm3OPDtY9u6rf/e4z7tA5lm3cIDjU7Uh2aflyz6PUNqH ihRHN1I1G8cyTCby1+ezSA== 0000950170-98-000685.txt : 19980408 0000950170-98-000685.hdr.sgml : 19980408 ACCESSION NUMBER: 0000950170-98-000685 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980407 SROS: NYSE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: FLEMINGTON PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0001043873 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222407152 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-53719 FILM NUMBER: 98589157 BUSINESS ADDRESS: STREET 1: 43 EMERY AVE CITY: FLEMINGTON STATE: NJ ZIP: 08820 BUSINESS PHONE: 9087823431 MAIL ADDRESS: STREET 1: 43 EMERY AVE CITY: FLEMINGTON STATE: NJ ZIP: 08822 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: WATSON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884629 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 953872914 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 311 BONNIE CIRCLE CITY: CORONA STATE: CA ZIP: 91720 BUSINESS PHONE: 9092701400 MAIL ADDRESS: STREET 1: 311 BONNIE CIRCLE CITY: CORONA STATE: CA ZIP: 91720 SC 13G 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. _____________)* FLEMINGTON PHARMACEUTICAL CORPORATION (Name of Issuer) (Name of Issuer) COMMON STOCK, $.01 PAR VALUE (Title of Class of Securities) (Title of Class of Securities) 339280 10 9 (CUSIP Number) NOVEMBER 12, 1997 (Date of Reportable Event) This Schedule is filed pursuant to: [ ] Rule 13d-1 (b) [ ] Rule 13d-1 (c) [X] Rule 13d-1 (d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13G - ------------------------------------------------------------------------------- CUSIP NO. 339280 10 9 - ------------------------------------------------------------------------------- - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Watson Pharmaceuticals, Inc., 95-3872914 - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) /X/ - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION a Nevada Corporation - ------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER SHARES BENEFICIALLY 389,350 OWNED BY ------------------------------------------------- EACH 6 SHARED VOTING POWER REPORTING 0 PERSON ------------------------------------------------- WITH 7 SOLE DISPOSITIVE POWER 389,350 ------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 - ------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 389,350 - ------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 10.0% - ------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------- *SEE INSTRUCTION BEFORE FILLING OUT! ITEM 1 (A)-(B) Name of Issuer: Flemington Pharmaceutical Corporation ("Issuer") 43 Emery Ave. Flemington, New Jersey 08822 ITEM 2 (A)-(C) Name of Person Filing: Watson Pharmaceuticals, Inc., a Nevada corporation ("Watson") 311 Bonnie Circle Corona, CA 91720 ITEM 2 (D) Title of Class of Securities: common stock, $ .01 par value ("Common Stock") ITEM 2 (E) CUSIP Number: 339280 10 9 ITEM 3 Watson acquired 389,350 shares of the Issuer's Common Stock through Watson's July 1995 acquisition of Circa Pharmaceuticals, Inc. ("Circa"). Circa acquired the Common Stock from the Issuer in November 1994, prior to the Issuer's November 1997 Initial Public Offering. This Schedule 13G is filed pursuant to Securities Exchange Act rule 13d-1(d). ITEM 4 Ownership: The following information is provided as of December 31, 1997: (a) Amount Beneficially Owned: 389,350 shares of Common Stock (b) Percent of Class: 10.0% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 389,350 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 389,350 (iv) shared power to dispose or to direct the disposition of: 0 ITEM 5 Ownership of Five Percent or Less of a Class: Not applicable ITEM 6 Ownership of More than Five Percent on Behalf of Another Person: Not applicable ITEM 9 Notice of Dissolution of Group: Not applicable ITEM 10 Certification: Not applicable SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. WATSON PHARMACEUTICALS, INC. April 7, 1998 ----------------------------------- Date /s/ ALLEN CHAO ----------------------------------- Signature Allen Chao, Ph.D., Chairman, President and Chief Executive Officer ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001). -----END PRIVACY-ENHANCED MESSAGE-----